Anbio Biotechnology (NNNN)
NasdaqGM · USD · Healthcare · Medical Instruments & Supplies
$3.70 (-2.89%) as of
Key statistics
- Market cap
- 162.40M
- P/E (TTM)
- 24.67
- EPS (TTM)
- 0.1500
- Dividend yield
- 0.00%
- 52-week range
- 3.0900 – 44.7300
- Revenue (TTM)
- 8.65M
- Profit margin
- 74.05%
- Volume
- 38.38k
About Anbio Biotechnology
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Frankfurt am Main, Germany
- Employees
- 27
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.